Cargando…

Reduced mucosal immunity to poliovirus after cessation of trivalent oral polio vaccine

The switch from using only trivalent oral polio vaccine (tOPV) to sequential schedules combining inactivated poliovirus vaccine (IPV) and bivalent oral polio vaccine (bOPV) for polio vaccination will cause changes to mucosal immunity against polio in infants, which plays an important role in prevent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Ting, Li, Jing, Shi, Hongyuan, Ye, Hui, Ma, Rufei, Fu, Yuting, Liu, Xiaochang, Li, Guoliang, Yang, Xiaolei, Zhao, Zhimei, Yang, Jingsi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475588/ https://www.ncbi.nlm.nih.gov/pubmed/33848232 http://dx.doi.org/10.1080/21645515.2021.1911213

Ejemplares similares

Influence of gut microbiota on mucosal IgA antibody response to the polio vaccine
por: Zhao, Ting, et al.
Publicado: (2020)

Environmental Surveillance of Polioviruses in Armenia, Colombia before Trivalent Oral Polio Vaccine Cessation
por: González, María Mercedes, et al.
Publicado: (2019)

Introduction of Inactivated Poliovirus Vaccine and Trivalent Oral Polio Vaccine/Bivalent Oral Polio Vaccine Switch in the African Region
por: Tevi-Benissan, Carol, et al.
Publicado: (2017)

Post hoc analysis of two clinical trials to compare the immunogenicity and safety of different polio immunization schedules in Chinese infants
por: Zhao, Ting, et al.
Publicado: (2021)

Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study
por: Taniuchi, Mami, et al.
Publicado: (2017)

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2016)

Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine–only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants
por: Brickley, Elizabeth B, et al.
Publicado: (2018)

Resource Needs for the Trivalent Oral Polio to Bivalent Oral Polio Vaccine Switch in Indonesia
por: Holmes, Marionette, et al.
Publicado: (2017)

Managing the Planned Cessation of a Global Supply Market: Lessons Learned From the Global Cessation of the Trivalent Oral Poliovirus Vaccine Market
por: Rubin, Jennifer, et al.
Publicado: (2017)

Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame
por: Parker, Edward PK, et al.
Publicado: (2015)

Immunity and field efficacy of type 2-containing polio vaccines after cessation of trivalent oral polio vaccine: A population-based serological study in Pakistan
por: Voorman, Arie, et al.
Publicado: (2020)

Vaccine-related poliovirus shedding in trivalent polio vaccine and human immunodeficiency virus status: analysis from under five children
por: Hassan, Joanne, et al.
Publicado: (2017)

Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine — Worldwide, 2013–2016
Publicado: (2015)

Type 2 poliovirus detection after global withdrawal of trivalent oral vaccine
por: Blake, Isobel M., et al.
Publicado: (2018)

Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2018)

The Switch From Trivalent to Bivalent Oral Poliovirus Vaccine in the South-East Asia Region
por: Bahl, Sunil, et al.
Publicado: (2017)

Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2018)

Circulating Vaccine Derived Poliovirus and the polio eradication endgame
por: Davis, Robert, et al.
Publicado: (2012)

Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame
por: Thompson, Kimberly M., et al.
Publicado: (2020)

Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review
por: Bandyopadhyay, Ananda S, et al.
Publicado: (2018)

Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine
por: Sáez-Llorens, Xavier, et al.
Publicado: (2022)

Protocol Paper: Oral Poliovirus Vaccine Transmissibility in Communities After Cessation of Routine Oral Poliovirus Vaccine Immunization
por: Sarnquist, Clea, et al.
Publicado: (2018)

Mucosal immunity to poliovirus
por: Connor, Ruth I., et al.
Publicado: (2021)

Experience With Inactivated Polio Vaccine Introduction and the “Switch” From Trivalent to Bivalent Oral Polio Vaccine in the World Health Organization’s Western Pacific Region
por: Gurung, Santosh, et al.
Publicado: (2017)

Preventing Vaccine-Derived Poliovirus Emergence during the Polio Endgame
por: Pons-Salort, Margarita, et al.
Publicado: (2016)

Financial Support to Eligible Countries for the Switch From Trivalent to Bivalent Oral Polio Vaccine—Lessons Learned
por: Shendale, Stephanie, et al.
Publicado: (2017)

Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2017)

Regulatory Aspects of Sabin Type 2 Withdrawal From Trivalent Oral Poliovirus Vaccine: Process and Lessons Learned
por: Decina, Daniela, et al.
Publicado: (2017)

Poliomyelitis seroprevalence in high risk populations of India before the trivalent-bivalent oral poliovirus vaccine switch in 2016
por: Ahmad, Mohammad, et al.
Publicado: (2021)

In-Vitro Inactivation of Sabin-Polioviruses for Development of Safe and Effective Polio Vaccine
por: Abd-Elghaffar, Asmaa A., et al.
Publicado: (2020)

Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy
por: DUINTJER TEBBENS, R. J., et al.
Publicado: (2017)

Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge
por: Hird, Thomas R., et al.
Publicado: (2012)

Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines—Lessons Learned From the Global Perspective
por: Ramirez Gonzalez, Alejandro, et al.
Publicado: (2017)

Assessing the Risks for Poliovirus Outbreaks in Polio-Free Countries — Africa, 2012–2013
Publicado: (2013)

Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication
por: Aghamohammadi, Asghar, et al.
Publicado: (2017)

Circulating vaccine-derived poliovirus: a menace to the end game of polio eradication
por: Ming, Long Chiau, et al.
Publicado: (2020)

The resurgence of wild poliovirus in Pakistan and Afghanistan: A new setback for polio eradication
por: Rana, Muhammad Suleman, et al.
Publicado: (2022)

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2016)

Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2?
por: Resik, Sonia, et al.
Publicado: (2018)

Re-emergence of vaccine-derived poliovirus in Israel, US, and UK – Call for promoting the use of novel oral polio vaccine
por: Shahnoor, Syeda, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6bdq4enrj9mukmtasjgvmf01l7